Paid Clinical Trials Washington, D.C.

Discover 803 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 803

Investigational CMV Vaccine Study for Volunteers Ages 9–15Investigational CMV Vaccine Study for Volunteers Ages 9–15

PHASE1

PHASE2

Sponsor:

Moderna

Location:

Washington DC, Baltimore MD, Frederick MD, Norfolk VAshow 43 more

Code:

NCT05575492

Conditions

Cytomegalovirus

Eligibility Criteria

Sex: All

Age: 9 - 15

Healthy Volunteers: Accepted

Interventions

mRNA-1647

Placebo

ImmunotherapyImmunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Recruiting

PHASE1

Sponsor:

Sabine Mueller, MD, PhD

Location:

Washington DC, Baltimore MD, Hackensack NJ, Durham NCshow 9 more

Code:

NCT04323046

Conditions

Glioblastoma

Malignant Glioma

Recurrent Glioblastoma

Recurrent Malignant Glioma

Recurrent Grade III Glioma

Eligibility Criteria

Sex: All

Age: 6 - 25

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Quality-of-Life Assessment

Questionnaire Administration

Observational StudyRegistry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

Recruiting

Sponsor:

Axogen Corporation

Location:

Washington DC, Bethesda MD, Baltimore MD, Richmond VAshow 33 more

Code:

NCT01526681

Conditions

Peripheral Nerve Injuries

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Processed Human Nerve Graft

Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.

Autogenous Nerve Graft

Nerve Tube Conduit

Autologous Breast Reconstruction with Neurotization

Adoptive Cord BloodAdoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

Recruiting

PHASE1

PHASE2

Sponsor:

Catherine Bollard

Location:

Washington DC, Houston TX

Code:

NCT03594981

Conditions

Viral Infection

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

CMV/AdV /EBV/BKV specific T cells

Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Washington DC, Frederick MD, Hershey PA, Chapel Hill NCshow 59 more

Code:

NCT05156281

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Washington DC, Baltimore MD, Richmond VA, Charlottesville VAshow 29 more

Code:

NCT05455320

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talquetamab

Daratumumab

Pomalidomide

Dexamethasone

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Washington DC, McLean VA, Kensington MD, Largo MDshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

NVL-655A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Recruiting

PHASE1

PHASE2

Sponsor:

Nuvalent Inc.

Location:

Washington DC, Baltimore MD, Philadelphia PA, New York NYshow 19 more

Code:

NCT05384626

Conditions

Locally Advanced Solid Tumor

Metastatic Solid Tumor

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

NVL-655

Trichostatin ATolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Recruiting

PHASE1

Sponsor:

Vanda Pharmaceuticals

Location:

Washington DC, Hackensack NJ, Lafayette IN, Fairway KSshow 1 more

Code:

NCT03838926

Conditions

Relapsed or Refractory Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Trichostatin A

Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Washington DC, Bethesda MD, Baltimore MD, Richmond VAshow 104 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

SeralutinibEfficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting

PHASE3

Sponsor:

GB002, Inc.

Location:

Washington DC, Falls Church VA, Baltimore MD, Richmond VAshow 51 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler